Health Matters
Printing is not available for Health Matters content.
Subscribers can read every article in full at health-matters.io.

Aspen Pharmacare Earnings Jump 22% on Mounjaro Demand

Aspen Pharmacare earnings rose 22% as demand for Eli Lilly's weight-loss drug Mounjaro surged, with the group also eyeing generic semaglutide.

This article is for Health Matters subscribers

Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

SubscribeLog in

Not ready to subscribe? Get Health Matters Weekly free: the week’s top healthcare headlines every Friday.

More from Health Matters

15.11.2026

Learn why the state wants the Constitutional Court to allow treatment instead of lump-sum payouts in medical negligence cases, and why critics object.

15.11.2026

Understand the challenges of mental health underwriting in life insurance and why insurers must adapt to new realities.

13.11.2026

Aspen share buybacks total R2.43bn as the Ovestin sale releases capital. Explore the earnings outlook and concerns over losing a high-margin product.